Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 06.10.2025 5 Am J Gastroenterol 1 Am J Pathol 5 Anticancer Res 1 BMC Cancer 10 BMC Gastroenterol 1 Dig Dis 7 PLoS One 1 Radiology 3 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. KIM WR, Mannalithara A, Charu V, Chung N, et al
   Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease.
   Am J Gastroenterol. 2025;120:2312-2320.
   PubMed         Abstract available
   
   
2. WU C, Targher G, Byrne CD, Mao Y, et al
   Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021.
   Am J Gastroenterol. 2025;120:2280-2290.
   PubMed         Abstract available
   
   
3. LEE HH, Lee HA, Kim EJ, Kim HY, et al
   Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study.
   Am J Gastroenterol. 2025;120:2321-2329.
   PubMed         Abstract available
   
   
4. RATTAN P, Ahn JC, Chara BS, Mullan AF, et al
   Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease.
   Am J Gastroenterol. 2025;120:2452-2456.
   PubMed         Abstract available
   
   
5. KHAN Z
   Continuing Medical Education Questions: October 2025.
   Am J Gastroenterol. 2025;120:2236.
   PubMed         Abstract available
   
   

   
   Am J Pathol

6. LI N, Wu S, Li X, Yan M, et al
   Peroxisome Proliferator-Activated Receptor Agonist IVA337 Alleviates Inflammation and Fibrosis in MASH by Restoring Lipid Homeostasis.
   Am J Pathol. 2025;195:1822-1838.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. KUWANO A, Yada M, Tanaka K, Hamomoto T, et al
   Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study.
   Anticancer Res. 2025;45:4627-4636.
   PubMed         Abstract available
   
   
8. KARASHIMA R, Masuda T, Nagayama Y, Adachi Y, et al
   Hepatic Pseudolipoma Mimicking Fat-containing Malignant Liver Tumor: A Case of Migration from the Pelvic Cavity.
   Anticancer Res. 2025;45:4653-4658.
   PubMed         Abstract available
   
   
9. TAKEDA S, Namisaki T, Koizumi A, Takaya H, et al
   The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma.
   Anticancer Res. 2025;45:4493-4507.
   PubMed         Abstract available
   
   
10. KITAOKA A, Oura K, Fujita K, Sasaki K, et al
    Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:4211-4229.
    PubMed         Abstract available
    
    
11. TAKAHASHI H, Kojima D, Miyasaka Y, Wada H, et al
    Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.
    Anticancer Res. 2025;45:4547-4564.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. CHUANG WY, Shen PC, Chiu SH, Huang WY, et al
    Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma.
    BMC Cancer. 2025;25:1449.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

13. EZEANI C, Omaliko C, Protiva P, Al-Ajlouni YA, et al
    Cancer disparities in lean vs. non-lean MASH: insight from a national inpatient sample.
    BMC Gastroenterol. 2025;25:659.
    PubMed         Abstract available
    
    
14. LIU C, Li C, Fu J, Bai L, et al
    Association between the TyG index and MAFLD and its subtypes: a population-based cross-sectional study.
    BMC Gastroenterol. 2025;25:652.
    PubMed         Abstract available
    
    
15. ALEM GB, Achenef DN, Kassie TA, Bezie GA, et al
    Portal vein thrombosis and associated factors among patients admitted to Tibebe Ghion hospital, Bahir Dar, Ethiopia: a cross-sectional study, 2021-2024.
    BMC Gastroenterol. 2025;25:646.
    PubMed         Abstract available
    
    
16. GONG Y, Li X, Wang M
    Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma.
    BMC Gastroenterol. 2025;25:658.
    PubMed         Abstract available
    
    
17. WANG X, Fan L
    Comparative efficacy and safety of endovascular intervention versus conservative therapy in Budd-Chiari syndrome: a retrospective cohort study.
    BMC Gastroenterol. 2025;25:680.
    PubMed         Abstract available
    
    
18. BAHRI MH, Navabian S, Akbari H, Bagherpour JZ, et al
    Impact of cholecystectomy on Metabolic dysfunction-Associated Steatotic Liver Disease and metabolic syndrome: a 6-month prospective cohort study.
    BMC Gastroenterol. 2025;25:671.
    PubMed         Abstract available
    
    
19. LIU HL, Liu X, Hu YF, Wang XX, et al
    Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis.
    BMC Gastroenterol. 2025;25:667.
    PubMed         Abstract available
    
    
20. TAYE B, Ayele YY, Achenef DN, Abeje G, et al
    Burden and determinants of upper gastrointestinal bleeding in cirrhotic patients: evidence from Sub-Saharan Africa, 2024.
    BMC Gastroenterol. 2025;25:679.
    PubMed         Abstract available
    
    
21. WU X, Chen Q, Zhang C, Hong X, et al
    The effect of longitudinal trajectories of triglyceride-glucose index on the incident metabolic dysfunction-associated steatotic liver disease.
    BMC Gastroenterol. 2025;25:689.
    PubMed         Abstract available
    
    
22. LI Z, Li X, Shao X, Xu Q, et al
    Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study.
    BMC Gastroenterol. 2025;25:676.
    PubMed         Abstract available
    
    

    
    Dig Dis

23. MANIKAT R, Tran S, Kam LY, Dronamraju D, et al
    Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis.
    Dig Dis. 2025;43:582-592.
    PubMed         Abstract available
    
    

    
    PLoS One

24. SUTTAWONG N, Witayavanitkul N, Chayanupatkul M, Wanpiyarat N, et al
    Gardenia jasminoides fruit extract ameliorates non-alcoholic steatohepatitis with fibrosis by modulating inflammatory and fibrogenic pathways.
    PLoS One. 2025;20:e0333800.
    PubMed         Abstract available
    
    
25. AL MAZROUEI N, ElGharbawy MM, Gamal M, Emad S, et al
    Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients.
    PLoS One. 2025;20:e0333581.
    PubMed         Abstract available
    
    
26. SU J, Sun F
    Uncovering biomarkers and molecular pathways linking NAFLD and AIS: Insights from bioinformatic analysis and experiment.
    PLoS One. 2025;20:e0333719.
    PubMed         Abstract available
    
    
27. HOLINKA M, Frankova S, Adamcova Selcanova S, Skladany L, et al
    Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression.
    PLoS One. 2025;20:e0333051.
    PubMed         Abstract available
    
    
28. ZHAO B, Qiu W, Xu W, Wu L, et al
    Regulatory influence of alpha-Pinene on MATN3 expression in hepatocellular carcinoma: Extending to pan-cancer analysis.
    PLoS One. 2025;20:e0330653.
    PubMed         Abstract available
    
    
29. TIAN M, Zhang Y, Liu Z, Zhao N, et al
    A new investigation of nonalcoholic fatty liver disease: Effects of hypoxia on mitochondrial function and lipid droplet autophagy.
    PLoS One. 2025;20:e0331305.
    PubMed         Abstract available
    
    
30. MON AM, Intuyod K, Klungsaeng S, Jusakul A, et al
    A circulating microRNA panel enhances the diagnosis of cholangiocarcinoma.
    PLoS One. 2025;20:e0333279.
    PubMed         Abstract available
    
    

    
    Radiology

31. WESSNER CE, Forsberg F, Lyshchik A, O'Kane P, et al
    Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.
    Radiology. 2025;316:e250083.
    PubMed         Abstract available
    
    

    
    Transplantation

32. BYRNE MM, Chavez-Villa M, Endo Y, Jimenez-Soto C, et al
    Live Donor Liver Transplantation for Oncologic Indications.
    Transplantation. 2025 Jun 11. doi: 10.1097/TP.0000000000005427.
    PubMed         Abstract available
    
    
33. GUO H, Gala-Lopez BL, Alwayn IPJ, Hewitt KC, et al
    Liver Discard Rate Attributable to Conservative Estimations of Steatosis: An Inference-based Approach.
    Transplantation. 2025;109:e609-e618.
    PubMed         Abstract available
    
    
34. MAGYAR CTJ, Jones O, Rajendran L, Carrique L, et al
    Living Donor Liver Transplantation for Alcohol-related Liver Disease: An Intention-to-treat Analysis.
    Transplantation. 2025 Apr 24. doi: 10.1097/TP.0000000000005410.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.